CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
Kyuho Kim, Sung Hee Choi
Diabetes Metab J. 2021;45(4):502-504.   Published online July 30, 2021
DOI: https://doi.org/10.4093/dmj.2021.0158

Excel Download

Cardiovascular Safety of SGLT2 Inhibitors Compared to DPP4 Inhibitors and Sulfonylureas as the Second-Line of Therapy in T2DM Using Large, Real-World Clinical Data in Korea
Diabetes & Metabolism Journal. 2021;45(4):502-504   Crossref logo
Link1 Link2 Link3

SGLT2 inhibitors cost effective versus sulfonylureas in T2DM
PharmacoEconomics & Outcomes News. 2019;842(1):29-29   Crossref logo
Link1 Link2 Link3

PDB7 DIABETIC COMPLICATIONS ASSOCIATED WITH SGLT2 AND DPP4 INHIBITORS: A REAL-WORLD APPROACH
Value in Health. 2019;22:S141   Crossref logo
Link1 Link2

The efficacy and safety of DPP4 inhibitors compared to sulfonylureas as add-on therapy to metformin in patients with Type 2 diabetes: A systematic review and meta-analysis
Diabetes Research and Clinical Practice. 2015;109(2):378-388   Crossref logo
Link1 Link2

393-P: SGLT2 Inhibitors Reduce Cardiovascular and Renal Risks Compared with GLP-1 Receptor Agonists and DPP4 Inhibitors in Patients with Diabetic Kidney Disease: A Systematic Review and Network Meta-analysis
Diabetes. 2022;71(Supplement_1):   Crossref logo
Link1 Link2

Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice
Advances in Therapy. 2019;36(10):2895-2909   Crossref logo
Link1 Link2 Link3

1211-P: Real-World Use of SGLT2 Inhibitors in a Large U.S. Safety-Net Health System
Diabetes. 2020;69(Supplement_1):   Crossref logo
Link1 Link2

Efficacy and Safety of Regorafenib with or without PD-1 Inhibitors as Second-Line Therapy for Advanced Hepatocellular Carcinoma in Real-World Clinical Practice
OncoTargets and Therapy. 2022;Volume 15:1079-1094   Crossref logo
Link1 Link2

Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
The Journal of Clinical Endocrinology & Metabolism. 2022;   Crossref logo
Link1 Link2

Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis
Diabetes/Metabolism Research and Reviews. 2016;33(1):e2818   Crossref logo
Link1 Link2 Link3